Published in N Engl J Med on December 28, 2000
Immunogenicity of 3+1 Versus 2+1 Schedule for PCV7 | NCT02040402
What happened to the streptococci: overview of taxonomic and nomenclature changes. Clin Microbiol Rev (2002) 5.81
Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis. Clin Microbiol Rev (2010) 3.58
Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999--2000, including a comparison of resistance rates since 1994--1995. Antimicrob Agents Chemother (2001) 3.23
Evaluation of a medium (STGG) for transport and optimal recovery of Streptococcus pneumoniae from nasopharyngeal secretions collected during field studies. J Clin Microbiol (2001) 2.92
Population genomics of post-vaccine changes in pneumococcal epidemiology. Nat Genet (2013) 2.63
Clonal distribution of invasive pneumococcal isolates from children and selected adults in the United States prior to 7-valent conjugate vaccine introduction. J Clin Microbiol (2003) 2.59
Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future. BMC Med (2011) 2.44
Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria. Antimicrob Agents Chemother (2004) 2.17
Managing antibiotic resistance. N Engl J Med (2000) 1.90
National hospitalization trends for pediatric pneumonia and associated complications. Pediatrics (2010) 1.86
Pediatric autoimmune neuropsychiatric disorders associated with streptococcus: comparison of diagnosis and treatment in the community and at a specialty clinic. Pediatrics (2008) 1.85
Pneumococcal serotypes before and after introduction of conjugate vaccines, United States, 1999-2011(1.). Emerg Infect Dis (2013) 1.84
Antimicrobial drug prescription in ambulatory care settings, United States, 1992-2000. Emerg Infect Dis (2003) 1.74
Emergence and spread of Streptococcus pneumoniae with erm(B) and mef(A) resistance. Emerg Infect Dis (2005) 1.74
Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995. Antimicrob Agents Chemother (2002) 1.70
Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother (2001) 1.69
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. Antimicrob Agents Chemother (2008) 1.66
beta-Arrestin 1 participates in platelet-activating factor receptor-mediated endocytosis of Streptococcus pneumoniae. Infect Immun (2005) 1.60
Impact of an antimicrobial utilization program on antimicrobial use at a large teaching hospital: a randomized controlled trial. Infect Control Hosp Epidemiol (2009) 1.60
Disease surveillance and the academic, clinical, and public health communities. Emerg Infect Dis (2003) 1.58
Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother (2003) 1.57
Efficiency of a pneumococcal opsonophagocytic killing assay improved by multiplexing and by coloring colonies. Clin Diagn Lab Immunol (2003) 1.54
Levofloxacin-resistant invasive Streptococcus pneumoniae in the United States: evidence for clonal spread and the impact of conjugate pneumococcal vaccine. Antimicrob Agents Chemother (2004) 1.53
Solution structure of choline binding protein A, the major adhesin of Streptococcus pneumoniae. EMBO J (2004) 1.47
Tensions in antibiotic prescribing: pitting social concerns against the interests of individual patients. J Gen Intern Med (2002) 1.47
Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian Ward Surveillance Study (CANWARD 2008). Antimicrob Agents Chemother (2010) 1.46
HIV-1 protease inhibitors from inverse design in the substrate envelope exhibit subnanomolar binding to drug-resistant variants. J Am Chem Soc (2008) 1.43
Emergence of Streptococcus pneumoniae with very-high-level resistance to penicillin. Antimicrob Agents Chemother (2004) 1.36
Invasive pneumococcal infections in Denmark from 1995 to 1999: epidemiology, serotypes, and resistance. Clin Diagn Lab Immunol (2002) 1.36
Impact of statewide program to promote appropriate antimicrobial drug use. Emerg Infect Dis (2005) 1.35
International Circumpolar Surveillance System for invasive pneumococcal disease, 1999-2005. Emerg Infect Dis (2008) 1.34
In vitro activities of broad-spectrum cephalosporins against nonmeningeal isolates of Streptococcus pneumoniae: MIC interpretation using NCCLS M100-S12 recommendations. J Clin Microbiol (2002) 1.32
Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada during 2000. Antimicrob Agents Chemother (2002) 1.30
What is the mechanism for persistent coexistence of drug-susceptible and drug-resistant strains of Streptococcus pneumoniae? J R Soc Interface (2009) 1.30
Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1-4. Ann Clin Microbiol Antimicrob (2008) 1.29
Changes in pneumococcal serotypes and antimicrobial resistance after introduction of the 13-valent conjugate vaccine in the United States. Antimicrob Agents Chemother (2014) 1.29
The "minimizing antibiotic resistance in Colorado" project: impact of patient education in improving antibiotic use in private office practices. Health Serv Res (2005) 1.25
Antibiotic prescribing for children. Too much and too little? Retrospective observational study in primary care. Br J Clin Pharmacol (2003) 1.25
Comparison of antibiotic resistance and serotype composition of carriage and invasive pneumococci among Bangladeshi children: implications for treatment policy and vaccine formulation. J Clin Microbiol (2003) 1.24
Macrolide efflux in Streptococcus pneumoniae is mediated by a dual efflux pump (mel and mef) and is erythromycin inducible. Antimicrob Agents Chemother (2005) 1.22
In vitro antibacterial activity and pharmacodynamics of new quinolones. Eur J Clin Microbiol Infect Dis (2003) 1.16
Aggregated antibiograms and monitoring of drug-resistant Streptococcus pneumoniae. Emerg Infect Dis (2003) 1.15
Pneumococcal vaccination and revaccination of older adults. Clin Microbiol Rev (2003) 1.15
Variation in outpatient antibiotic prescribing in the United States. Am J Manag Care (2009) 1.15
Prevalence of single mutations in topoisomerase type II genes among levofloxacin-susceptible clinical strains of Streptococcus pneumoniae isolated in the United States in 1992 to 1996 and 1999 to 2000. Antimicrob Agents Chemother (2002) 1.15
Caregivers' practices, knowledge and beliefs of antibiotics in paediatric upper respiratory tract infections in Trinidad and Tobago: a cross-sectional study. BMC Fam Pract (2004) 1.14
Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia. BMC Pulm Med (2009) 1.13
Nasopharyngeal carriage of antimicrobial-resistant Streptococcus pneumoniae among young children attending 79 kindergartens and day care centers in Hong Kong. Antimicrob Agents Chemother (2001) 1.12
Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy. Antimicrob Agents Chemother (2004) 1.08
Changes in capsule and drug resistance of Pneumococci after introduction of PCV7, Japan, 2010-2013. Emerg Infect Dis (2014) 1.07
Decrease in antibiotic use among children in the 1990s: not all antibiotics, not all children. CMAJ (2004) 1.06
Association of serotypes of Streptococcus pneumoniae with age in invasive pneumococcal disease. J Clin Microbiol (2010) 1.05
Fluoroquinolone resistance in invasive Streptococcus pyogenes isolates due to spontaneous mutation and horizontal gene transfer. Antimicrob Agents Chemother (2006) 1.04
Telithromycin- and fluoroquinolone-resistant Streptococcus pneumoniae in Taiwan with high prevalence of resistance to macrolides and beta-lactams: SMART program 2001 data. Antimicrob Agents Chemother (2003) 1.04
Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. Antimicrob Agents Chemother (2003) 1.03
Baseline study to determine in vitro activities of daptomycin against gram-positive pathogens isolated in the United States in 2000-2001. Antimicrob Agents Chemother (2003) 1.00
Streptococcus pneumoniae, Brooklyn, New York: fluoroquinolone resistance at our doorstep. Emerg Infect Dis (2002) 1.00
Induction of gamma interferon and nitric oxide by truncated pneumolysin that lacks pore-forming activity. Infect Immun (2002) 1.00
Improving therapeutic strategies for secondary bacterial pneumonia following influenza. Future Microbiol (2008) 0.99
Revising the role of the pneumococcal vex-vncRS locus in vancomycin tolerance. J Bacteriol (2004) 0.99
Evidence for soft selective sweeps in the evolution of pneumococcal multidrug resistance and vaccine escape. Genome Biol Evol (2014) 0.98
Pathophysiology and treatment of bacterial meningitis. Ther Adv Neurol Disord (2009) 0.98
Novel antibacterial class. Antimicrob Agents Chemother (2003) 0.98
Temporal Variations among Invasive Pneumococcal Disease Serotypes in Children and Adults in Germany (1992-2008). Int J Microbiol (2010) 0.97
Fluoroquinolone and other antimicrobial resistance in invasive pneumococci, Hong Kong, 1995-2001. Emerg Infect Dis (2004) 0.97
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study. Antimicrob Agents Chemother (2007) 0.97
Nasopharyngeal carriage of Streptococcus pneumoniae in healthy children: implications for the use of heptavalent pneumococcal conjugate vaccine. Emerg Infect Dis (2002) 0.97
Geographic and temporal trends in antimicrobial nonsusceptibility in Streptococcus pneumoniae in the post-vaccine era in the United States. J Infect Dis (2013) 0.96
Identification and characteristics of vaccine refusers. BMC Pediatr (2009) 0.96
In vitro activities of garenoxacin (BMS-284756) against Streptococcus pneumoniae, viridans group streptococci, and Enterococcus faecalis compared to those of six other quinolones. Antimicrob Agents Chemother (2003) 0.95
Risk factors for development of multiple-class resistance to Streptococcus pneumoniae Strains in Belgium over a 10-year period: antimicrobial consumption, population density, and geographic location. Antimicrob Agents Chemother (2007) 0.95
Comparison of automated ribotyping to pulsed-field gel electrophoresis for genetic fingerprinting of Streptococcus pneumoniae. J Clin Microbiol (2001) 0.95
In vitro activities of the novel cephalosporin LB 11058 against multidrug-resistant Staphylococci and Streptococci. Antimicrob Agents Chemother (2004) 0.94
In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae. Antimicrob Agents Chemother (2007) 0.94
Increase in pilus islet 2-encoded pili among Streptococcus pneumoniae isolates, Atlanta, Georgia, USA. Emerg Infect Dis (2010) 0.93
Pharmacodynamic modeling of clarithromycin against macrolide-resistant [PCR-positive mef(A) or erm(B)] Streptococcus pneumoniae simulating clinically achievable serum and epithelial lining fluid free-drug concentrations. Antimicrob Agents Chemother (2002) 0.93
Macrolide resistance in adults with bacteremic pneumococcal pneumonia. Emerg Infect Dis (2006) 0.92
Activities of cethromycin and telithromycin against recent North American isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother (2004) 0.92
In vivo antibacterial activity of RWJ-54428, a new cephalosporin with activity against gram-positive bacteria. Antimicrob Agents Chemother (2003) 0.92
Clinician knowledge and beliefs after statewide program to promote appropriate antimicrobial drug use. Emerg Infect Dis (2005) 0.91
Procalcitonin-guided diagnosis and antibiotic stewardship revisited. BMC Med (2017) 0.91
Oropharyngeal colonization by Streptococcus pneumoniae among HIV-infected adults in Uganda: assessing prevalence and antimicrobial susceptibility. Int J Infect Dis (2006) 0.90
Pharmacodynamics of RWJ-54428 against Staphylococcus aureus, Streptococcus pneumoniae, and Enterococcus faecalis in a neutropenic mouse thigh infection model. Antimicrob Agents Chemother (2007) 0.90
Targeting imperfect vaccines against drug-resistance determinants: a strategy for countering the rise of drug resistance. PLoS One (2013) 0.90
Emerging Infections Program as Surveillance for Antimicrobial Drug Resistance. Emerg Infect Dis (2015) 0.89
Systemic antibiotics and tooth loss in periodontal disease. J Dent Res (2008) 0.89
Frequent beneficial mutations during single-colony serial transfer of Streptococcus pneumoniae. PLoS Genet (2011) 0.89
Reducing inappropriate antibiotic use among children with influenza infection. Can Fam Physician (2011) 0.89
Cost-effectiveness analysis of treatment options for acute otitis media. Ann Fam Med (2007) 0.89
Sentinel surveillance: a reliable way to track antibiotic resistance in communities? Emerg Infect Dis (2002) 0.88
Social-economic factors and irrational antibiotic use as reasons for antibiotic resistance of bacteria causing common childhood infections in primary healthcare. Eur J Pediatr (2011) 0.87
Improvements in antimicrobial prescribing for treatment of upper respiratory tract infections through provider education. J Gen Intern Med (2005) 0.87
Antibiotic-resistant invasive pediatric Streptococcus pneumoniae clones in Israel. J Clin Microbiol (2003) 0.87
Detection of resistance to gatifloxacin and moxifloxacin in Streptococcus pneumoniae with the VITEK 2 instrument. J Clin Microbiol (2004) 0.87
Antibiotics for lower respiratory tract infections. Still too frequently prescribed? Can Fam Physician (2004) 0.86
Antimicrobial resistance among isolates causing invasive pneumococcal disease before and after licensure of heptavalent conjugate pneumococcal vaccine. PLoS One (2009) 0.86
Risk factors for multidrug-resistant invasive pneumococcal disease in South Africa, a setting with high HIV prevalence, in the prevaccine era from 2003 to 2008. Antimicrob Agents Chemother (2012) 0.86
Factors associated with antimicrobial resistance and mortality in pneumococcal bacteremia. J Emerg Med (2007) 0.86
Invasive pneumococcal disease after implementation of 13-valent conjugate vaccine. Pediatrics (2014) 0.85
Clinical isolates of Streptococcus pneumoniae with different susceptibilities to ceftriaxone and cefotaxime. Antimicrob Agents Chemother (2003) 0.85
Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med (2005) 12.75
Genital human papillomavirus infection in female university students as determined by a PCR-based method. JAMA (1991) 6.83
Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N Engl J Med (2000) 6.58
A population-based assessment of invasive disease due to group B Streptococcus in nonpregnant adults. N Engl J Med (1993) 6.18
Bacterial meningitis in the United States in 1995. Active Surveillance Team. N Engl J Med (1997) 5.73
The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. N Engl J Med (1995) 5.18
Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era. JAMA (2001) 4.90
Syndrome of Rochalimaea henselae adenitis suggesting cat scratch disease. Ann Intern Med (1993) 4.88
Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA (1993) 4.63
The changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis (1999) 4.37
Practical disk diffusion method for detection of inducible clindamycin resistance in Staphylococcus aureus and coagulase-negative staphylococci. J Clin Microbiol (2003) 4.31
Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. N Engl J Med (2000) 4.20
Determinants of genital human papillomavirus infection in young women. J Natl Cancer Inst (1991) 4.14
Serogroup C meningococcal outbreaks in the United States. An emerging threat. JAMA (1995) 3.64
Group B streptococcal disease in the United States, 1990: report from a multistate active surveillance system. MMWR CDC Surveill Summ (1992) 3.57
National collaborative study of the prevalence of antimicrobial resistance among clinical isolates of Haemophilus influenzae. Antimicrob Agents Chemother (1988) 3.40
Serotype distribution of invasive group B streptococcal isolates in Maryland: implications for vaccine formulation. Maryland Emerging Infections Program. J Infect Dis (1998) 3.18
Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med (2000) 3.09
Invasive group B streptococcal disease in adults. A population-based study in metropolitan Atlanta. JAMA (1991) 3.09
Rapid penicillinase paper strip test for detection of beta-lactamase-producing Haemophilus influenzae and Neisseria gonorrhoeae. Antimicrob Agents Chemother (1977) 3.02
An outbreak of type A botulism associated with a commercial cheese sauce. Ann Intern Med (1996) 2.98
Reduction in the incidence of human listeriosis in the United States. Effectiveness of prevention efforts? The Listeriosis Study Group. JAMA (1995) 2.97
Invasive group B streptococcal disease: the emergence of serotype V. J Infect Dis (1996) 2.85
Methicillin-resistant Staphylococcus aureus as a community organism. Clin Infect Dis (1995) 2.80
Risk factors for group B streptococcal disease in adults. Ann Intern Med (1995) 2.78
Prevalence of antimicrobial resistance among clinical isolates of Haemophilus influenzae: a collaborative study. Diagn Microbiol Infect Dis (1986) 2.77
Simplified medium for ampicillin susceptibility testing of Haemophilus influenzae. Antimicrob Agents Chemother (1975) 2.71
Comparative evaluation of the Limulus assay and the direct Gram stain for detection of significant bacteriuria. Am J Clin Pathol (1975) 2.69
Active bacterial core surveillance of the emerging infections program network. Emerg Infect Dis (2001) 2.65
Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health (2000) 2.57
Cryptococcosis: population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. Cryptococcal Active Surveillance Group. J Infect Dis (1999) 2.57
Widespread West Nile virus activity, eastern United States, 2000. Emerg Infect Dis (2001) 2.52
Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA (2001) 2.40
Multistate evaluation of anonymous HIV testing and access to medical care. Multistate Evaluation of Surveillance of HIV (MESH) Study Group. JAMA (1998) 2.36
Candida dubliniensis fungemia: the first four cases in North America. Emerg Infect Dis (2000) 2.34
Invasive disease due to Haemophilus influenzae serotype f: clinical and epidemiologic characteristics in the H. influenzae serotype b vaccine era. The Haemophilus influenzae Study Group. Clin Infect Dis (1996) 2.33
Serogroup-specific epidemiology of Streptococcus pneumoniae: associations with age, sex, and geography in 7,000 episodes of invasive disease. Clin Infect Dis (1996) 2.29
Escherichia coli O157:H7 infection from a manured garden. Lancet (1993) 2.27
Acute retrovirus syndrome among prospectively identified homosexual men with incident HIV infection in Brazil. Projecto Praça Onze Study Group. J Acquir Immune Defic Syndr (2000) 2.19
Role of foods in sporadic listeriosis. II. Microbiologic and epidemiologic investigation. The Listeria Study Group. JAMA (1992) 2.15
Disk diffusion susceptibility testing of Haemophilus influenzae using haemophilus test medium. Eur J Clin Microbiol Infect Dis (1990) 2.12
Activities of aztreonam and new cephalosporins against infrequently isolated gram-negative bacilli. Antimicrob Agents Chemother (1983) 2.11
Coinfection with human T-cell lymphotropic virus type I and HIV in Brazil. Impact on markers of HIV disease progression. JAMA (1994) 2.11
Preparation, sensitivity, and specificity of Limulus lysate for endotoxin assay. Appl Microbiol (1973) 2.09
In vitro activities of moxalactam and cefotaxime against aerobic gram-negative bacilli. Antimicrob Agents Chemother (1980) 2.06
Group A meningococcal carriage in travelers returning from Saudi Arabia. JAMA (1988) 2.06
The 1997 AAP guidelines for prevention of early-onset group B streptococcal disease. American Academy of Pediatrics. Pediatrics (1997) 2.04
A population-based estimate of the burden of diarrhoeal illness in the United States: FoodNet, 1996-7. Epidemiol Infect (2002) 2.03
Detection of Tn917-like sequences within a Tn916-like conjugative transposon (Tn3872) in erythromycin-resistant isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother (1998) 2.03
Care-seeking for fatal illnesses in young children in Indramayu, west Java, Indonesia. Lancet (1993) 2.02
The accuracy of late antenatal screening cultures in predicting genital group B streptococcal colonization at delivery. Obstet Gynecol (1996) 1.99
Clinical and molecular epidemiology of vancomycin-resistant Enterococcus faecium during its emergence in a city in southern Texas. Clin Infect Dis (1995) 1.97
Epidemiology of bacterial meningitis in Niamey, Niger, 1981-96. Bull World Health Organ (1999) 1.96
Comparison of ribotyping and multilocus enzyme electrophoresis for subtyping of Listeria monocytogenes isolates. J Clin Microbiol (1994) 1.96
Bacteriologic and pharmacodynamic aspects of nalidixic acid. J Urol (1970) 1.95
Reappraisal of the antimicrobial susceptibilities of Chryseobacterium and Flavobacterium species and methods for reliable susceptibility testing. Antimicrob Agents Chemother (1997) 1.95
Name-based surveillance and public health interventions for persons with HIV infection. Multistate Evaluation of Surveillance for HIV Study Group. Ann Intern Med (1999) 1.94
Rapid selection of complement-inhibiting protein variants in group A Streptococcus epidemic waves. Nat Med (1999) 1.92
Meningococcal disease in Los Angeles County, California, and among men in the county jails. N Engl J Med (1996) 1.89
Xenorhabdus luminescens (DNA hybridization group 5) from human clinical specimens. J Clin Microbiol (1989) 1.88
Typhoid fever. An epidemic with remarkably few clinical signs and symptoms. Arch Intern Med (1984) 1.88
Failure of ceftazidime-amikacin therapy for bacteremia and meningitis due to Klebsiella pneumoniae producing an extended-spectrum beta-lactamase. Antimicrob Agents Chemother (1990) 1.87
Risk factors for invasive pneumococcal disease in children: a population-based case-control study in North America. Pediatrics (1999) 1.85
Azithromycin prophylaxis during a hospital outbreak of Mycoplasma pneumoniae pneumonia. J Infect Dis (2001) 1.85
Adverse and beneficial secondary effects of mass treatment with azithromycin to eliminate blindness due to trachoma in Nepal. Clin Infect Dis (2002) 1.84
Immunization of six-month-old infants with different doses of Edmonston-Zagreb and Schwarz measles vaccines. N Engl J Med (1990) 1.82
Risk factors for severe pulmonary and disseminated coccidioidomycosis: Kern County, California, 1995-1996. Clin Infect Dis (2001) 1.82
Sensitive bioassay for ketoconazole in serum and cerebrospinal fluid. Antimicrob Agents Chemother (1981) 1.77
Outbreaks in highly vaccinated populations: implications for studies of vaccine performance. Am J Epidemiol (1994) 1.77
Methods for improved detection of oxacillin resistance in coagulase-negative staphylococci: results of a multicenter study. J Clin Microbiol (1999) 1.76
The immunobiology of leishmaniasis. Rev Infect Dis (1983) 1.76
In vitro activity of LY146032 (daptomycin) against selected aerobic bacteria. Eur J Clin Microbiol (1987) 1.76
In vitro antimicrobial susceptibility testing of Borrelia burgdorferi: a microdilution MIC method and time-kill studies. J Clin Microbiol (1992) 1.75
A nosocomial outbreak of fluoroquinolone-resistant salmonella infection. N Engl J Med (2001) 1.72
Identification of coagulase-negative staphylococci with the API STAPH-IDENT system. J Clin Microbiol (1983) 1.70
Quantitative susceptibility test methods in major United States medical centers. Antimicrob Agents Chemother (1981) 1.70